The Nasdaq 100 has approached correction territory as chipmakers face renewed selling pressure. Concerns center on China's accelerating semiconductor advances, which may be outpacing previous expectations.
A broad chipmaker decline has triggered losses across the Nasdaq 100, with the index nearing a 10% drop from recent highs. The selloff reflects growing investor anxiety over China's chip sector progress.
Recent developments in Beijing's semiconductor capabilities have sparked questions about the pace of technological advancement in the region. Analysts point to signs that China may be closing the gap with Western chipmakers faster than initially anticipated.
The market reaction underscores sensitivity around semiconductor supply chains and geopolitical competition in critical technology sectors. Chipmakers have become focal points for investors tracking both technological innovation and international trade dynamics.
The decline weighs on a sector that has driven much of the recent market rally. Any sustained weakness in chip stocks could amplify broader market volatility as investors reassess valuations across the technology space.
The Senate has advanced the latest version of the Kids Online Safety Act out of committee. The House passed its own version of the contentious bill in June.
Matt McLennan, head of First Eagle Investments' Global Value Team, warns that excessive market focus on artificial intelligence has created dangerous complacency among investors.
Flipkart's payments app Super.money is expanding into e-commerce, enabling users to purchase items through interest-free installment plans. The move broadens the company's fintech offerings beyond payments.
The FDA has approved Moderna's mFLUSIVA, an mRNA-based flu vaccine for adults 50 and older. The approval marks the first seasonal flu vaccine using messenger RNA technology.